Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Nov 06, 2023 3:44pm
136 Views
Post# 35720064

RE:RE:New Filing today

RE:RE:New Filing today

I just read for the first time the 5 th amendment!!!
I dont quite see how you have determined that the LTM adjusted ebitda wont be met
You surely dont have access to the amount of the numerous adjustments which in most cases increases the EBITDA .....ADJUSTED as defined is way above Ebitda under GAAP
 

PWIB123 wrote: I scanned it.  Looks like the totality of all changes over 5 separate amendments and what was presented before.  I'm assuming they know they aren't going to be able to meet the trailing 12 month EBITDA (LTM EBITDA) requirements and the associated higher cash balances without raising the additional capital.  Or, they truly did only raise the additional capital to save their jobs.  Either way, we have been completely misled.  There's zero accountability.

 

<< Previous
Bullboard Posts
Next >>